CAS: 1597-32-6; 2-Amino-6-Fluoropyridine

相似化合物

325707-66-2 1390641-19-6 891856-23-8

上下游产品

CAS号1513-65-1 2,6-二氟吡啶 | CAS号258343-71-4 Acetamide, N-(6... | CAS号1075-62-3 N-乙酰基-1,6-二氨基吡啶 | CAS号944401-67-6 2-氨基-6-氟吡啶-5-硼酸频那醇酯 | CAS号878197-67-2 5-氟咪唑并[1,2-a]吡啶-2-甲醛 | CAS号1001070-25-2 Carbamic acid,N... | CAS号878197-91-2 2-(Dichlorometh... | CAS号878198-71-1 2-(Chloromethyl... | CAS号944401-65-4 2-氨基-5-溴-6-氟吡啶

2,6-二氟吡啶置于ammonium Hydroxide体系中,125.0 °C,1.4 Mpa 条件下,反应 5.0H,以92%的收率获得2-氨基-6-氟吡啶
参考文献:大规模合成具有环12π-电子环系统的新环嗪,5-Thia-1,8 B-二氮杂ena烯-3-羧酸衍生物
标题:大规模合成具有环12π-电子环系统的新环嗪,5-Thia-1,8 B-二氮杂ena烯-3-羧酸衍生物
摘要:5-Thia-1,8B-二氮杂ena烯(2及其酯8)是新的环嗪,其中顺磁环存在于外围的12π电子环系统中.已经开发了三种方便的制备方法8.其中一项涉及新化合物5-氟咪唑并[1,2-A ]吡啶(6B)的巯基乙醇化反应,然后进行duff反应,无需色谱纯化即可得到64%收率的8.
Doi:10.1016/s0040-4020(01)01171-1

专利信息

专利号:US-8252930-B2
优先权日:2006-07-06
标 题:Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
发明人：STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G
权利人:STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G; SOLVAY PHARM BV
摘要:Azaindole derivatives of formula (I): n nwherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.

专利号:EP-2041131-B1
优先权日:2006-07-06
标 题 :Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
发明人：STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G
权利人:ABBOTT HEALTHCARE PRODUCTS BV
摘要:The invention concerns azaindole derivatives having the general formula (I) wherein the symbols have the meanings given in the specification. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.

专利号:US-2023119463-A1
优先权日:2019-12-27
标题 :1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
发明人：CHEN YI
权利人:NEWAVE PHARMACEUTICAL INC
摘要:The present invention relates to 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

专利号:US-11731956-B2
优先权日:2018-10-22
标 题:Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

专利号:WO-2021133817-A1
优先权日:2019-12-27
标题 :1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
发明人：CHEN YI
权利人:GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD; NEWAVE PHARMACEUTICAL INC
摘要:The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).